Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice

Glioblastoma (GBM) causes poor survival in patients even with aggressive treatment. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment but resistance always ensues. Protein kinase CK2 (CK2) contributes to tumour development and proliferation in cancer, and it is overexpress...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Pharmaceuticals
المؤلفون الرئيسيون:	Laura Ferrer-Font, Lucia Villamañan, Nuria Arias-Ramos, Jordi Vilardell, Maria Plana, Maria Ruzzene, Lorenzo A. Pinna, Emilio Itarte, Carles Arús, Ana Paula Candiota
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2017-02-01
الموضوعات:	Glioma preclinical brain tumour GBM therapeutic target CK2 inhibitors CX-4945 metronomic therapy immune system
الوصول للمادة أونلاين:	http://www.mdpi.com/1424-8247/10/1/24